MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) announced today that Exosome
Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate
Test At-Home Collection Kit for patients who are concerned about
their prostate health. Millions of men recently had appointments
cancelled for important procedures, like biopsy, to detect the
presence of prostate cancer due to Shelter in Place orders issued
to reduce the spread of Covid-19. The at-home collection kit
provides an immediate and cost-effective solution that enables a
telemedicine/telehealth opportunity for physicians and their
patients who share frustration, anxiety and fear over whether the
patient harbors high-grade prostate cancer.
The ExoDx Prostate or EPI test is a urine-based, genomic test
that helps inform the prostate biopsy decision. This liquid biopsy
test recently received coverage in the VA Healthcare system through
a General Services Administration (GSA) award and is included in
the National Cancer Comprehensive Network (NCCN) guidelines for
early detection in men for both initial and repeat biopsy. It is
performed by Exosome Diagnostics, a Bio-Techne brand, in its CLIA,
ISO, NY certified and CAP-accredited laboratory located in
Waltham, Massachusetts. The EPI
test is a risk assessment tool that assists both physicians and
their patients with determining if a prostate biopsy is needed when
presented with an ambiguous PSA test result, and discriminates
between low and high grade prostate cancer, thereby allowing
physicians to perform the right intervention, for the right
patient, at the right time.
Physicians can trigger an order using a HIPAA-secure electronic
order form. The ExoDx Patient At- Home Collection Kit will ship
directly to the patient, allowing him to collect a urine specimen
in the safety, comfort and convenience of his own home. After
the sample is processed in the laboratory, the physician will
receive an electronic result report and counsel the
patient.
"I've used the ExoDx Prostate Test in clinical practice and
found it's a useful test to prioritize which patients need to
proceed sooner to biopsy or defer prostate biopsy for the time
being" said Dr. Liam Hurley.
"In some cases, the patient will be able to safely defer biopsy,
and I want to provide my patient this information with a high
degree of confidence that this genomic test provides. In other
cases, if the ExoDx Prostate Test informs a significant risk of
high-grade prostate cancer, I'll use the result to justify the need
for a biopsy."
"We are pleased to provide another solution for our customers
that are unable to see a healthcare professional during the current
pandemic," commented Chuck Kummeth,
President and Chief Executive Officer of Bio-Techne. "Based
on the enthusiasm and eagerness from urology experts and key
opinion leaders about this initiative, we expect the ExoDx Prostate
At-Home Collection Kit to benefit adoption of the test while
helping physicians better manage their patients and possibly save
lives during this trying time."
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Senior
Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-technes-exosome-diagnostics-launches-exodx-prostate-at-home-collection-kit-301040767.html
SOURCE Bio-Techne Corporation